Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels

Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.

. 2006 ; 149 (9) : 4517-4524.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc07523542
E-zdroje Online

NLK Free Medical Journals od 1997 do Před 1 rokem
Open Access Digital Library od 1997-01-01

We studied the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation on serum concentrations and tissue expression of resistin, adiponectin, and adiponectin receptor-1 and -2 (AdipoR1 and AdipoR2) mRNA in normal mice and mice with insulin resistance induced by lipogenic, simple-carbohydrate diet (LD). Sixteen weeks of LD feeding induced obesity with liver steatosis and increased insulin levels but did not significantly affect circulating adiponectin or resistin. Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Euglycemic-hyperinsulinemic clamp demonstrated the development of whole-body and liver insulin resistance in LD-fed mice, which were both normalized by fenofibrate. Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only. Fat adiponectin mRNA expression was not affected by fenofibrate treatment. Resistin mRNA expression increased in subcutaneous but not gonadal fat after fenofibrate treatment. In addition to fat, a significant amount of adiponectin mRNA was also expressed in the muscle. This expression markedly increased after fenofibrate treatment in chow- but not in LD-fed mice. Adipose tissue expression of AdipoR1 mRNA was significantly reduced in LD-fed mice and increased after fenofibrate treatment. In conclusion, PPAR-alpha activation ameliorated the development of insulin resistance in LD-fed mice despite a major increase in serum resistin levels. This effect could be partially explained by increased AdipoR1 expression in adipose tissue after fenofibrate treatment.

000      
00000naa 2200000 a 4500
001      
bmc07523542
003      
CZ-PrNML
005      
20111210135730.0
008      
090520s2006 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Haluzík, Martin, $d 1970- $7 xx0000707
245    10
$a Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels / $c Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.
314    __
$a Third Department of Medicine, First Faculty of Medicine and General University Hospital, Charles University, 128 08 Prague, Czech Republic. mhalu@lf1.cuni.cz
520    9_
$a We studied the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation on serum concentrations and tissue expression of resistin, adiponectin, and adiponectin receptor-1 and -2 (AdipoR1 and AdipoR2) mRNA in normal mice and mice with insulin resistance induced by lipogenic, simple-carbohydrate diet (LD). Sixteen weeks of LD feeding induced obesity with liver steatosis and increased insulin levels but did not significantly affect circulating adiponectin or resistin. Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Euglycemic-hyperinsulinemic clamp demonstrated the development of whole-body and liver insulin resistance in LD-fed mice, which were both normalized by fenofibrate. Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only. Fat adiponectin mRNA expression was not affected by fenofibrate treatment. Resistin mRNA expression increased in subcutaneous but not gonadal fat after fenofibrate treatment. In addition to fat, a significant amount of adiponectin mRNA was also expressed in the muscle. This expression markedly increased after fenofibrate treatment in chow- but not in LD-fed mice. Adipose tissue expression of AdipoR1 mRNA was significantly reduced in LD-fed mice and increased after fenofibrate treatment. In conclusion, PPAR-alpha activation ameliorated the development of insulin resistance in LD-fed mice despite a major increase in serum resistin levels. This effect could be partially explained by increased AdipoR1 expression in adipose tissue after fenofibrate treatment.
650    _2
$a financování organizované $7 D005381
650    _2
$a adiponektin $x genetika $x krev $7 D052242
650    _2
$a tuková tkáň $x chemie $x patologie $7 D000273
650    _2
$a zvířata $7 D000818
650    _2
$a krevní glukóza $x analýza $7 D001786
650    _2
$a dieta $7 D004032
650    _2
$a dietní sacharidy $x aplikace a dávkování $7 D004040
650    _2
$a kyseliny mastné neesterifikované $x analýza $7 D005230
650    _2
$a ztučnělá játra $x etiologie $x farmakoterapie $x krev $7 D005234
650    _2
$a exprese genu $x účinky léků $7 D015870
650    _2
$a glykemický clamp $7 D015309
650    _2
$a inzulin $x farmakologie $x krev $7 D007328
650    _2
$a inzulinová rezistence $7 D007333
650    _2
$a lipidy $x biosyntéza $7 D008055
650    _2
$a játra $x chemie $x účinky léků $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a kosterní svaly $x chemie $7 D018482
650    _2
$a obezita $x etiologie $x krev $x patofyziologie $7 D009765
650    _2
$a velikost orgánu $x účinky léků $7 D009929
650    _2
$a PPAR alfa $x agonisté $x fyziologie $7 D047493
650    _2
$a fenofibrát $x aplikace a dávkování $7 D011345
650    _2
$a messenger RNA $x analýza $7 D012333
650    _2
$a receptory adiponektinu $7 D054419
650    _2
$a receptory buněčného povrchu $x genetika $7 D011956
650    _2
$a resistin $x genetika $x krev $7 D052243
650    _2
$a triglyceridy $x krev $7 D014280
650    _2
$a hmotnostní úbytek $x účinky léků $7 D015431
700    1_
$a Lacinová, Zdeňka $7 xx0062138
700    1_
$a Dolinková, Markéta $7 xx0075951
700    1_
$a Haluzíková, Denisa, $d 1970- $7 jo2003163140
700    1_
$a Housa, Daniel, $d 1975- $7 xx0076895
700    1_
$a Hořínek, Aleš, $d 1961- $7 xx0061416
700    1_
$a Vernerová, Zdenka, $d 1960-2020 $7 jo2002104672
700    1_
$a Kumštýřová, T. $7 _BN001103
700    1_
$a Haluzík, Michal $7 xx0063775
773    0_
$w MED00009600 $t Endocrinology $g Roč. 149, č. 9 (2006), s. 4517-4524 $x 0013-7227
910    __
$a ABA008 $b x $y 9
990    __
$a 20090310084605 $b ABA008
991    __
$a 20091004161409 $b ABA008
999    __
$a ok $b bmc $g 655580 $s 508890
BAS    __
$a 3
BMC    __
$a 2006 $b 149 $c 9 $d 4517-4524 $i 0013-7227 $m Endocrinology $x MED00009600
LZP    __
$a 2009-B3/ipme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...